NMP22 was approved as a diagnostic biomarker by the Food And Drug Administration (FDA) (Bladdercheck), but this biomarker is not recommended for routine use because of its variable sensitivity (37.9–88.5%), depending mostly on the grade and stage, and specificity (65.2–96.9%) in bladder cancer detection [36]. This evidence concerns the gene NUMA1 and urinary bladder cancer.